Delirium at the Intensive Care Unit - a Retrospective Cohort Study

June 29, 2018 updated by: Stine Estrup, Zealand University Hospital

This project seeks to describe the incidence of delirium in the Intensive Care Unit (ICU) and to identify risk and preventive factors associated with development of delirium.

Especially, the investigators want to investigate if an imitated natural light/dark cycle influences frequency of delirium.

Study Overview

Status

Completed

Detailed Description

A common problem for patients in the ICU is episodes of delirium. Recent trials have described incidences ranging from 60-87% of patients in a number of different countries. Delirium is a condition with fluctuating conscience, disorganized thinking and disturbance of the sleep/wake cycle. Many patients with delirium experience hallucinations and agitation which can be very unpleasant for both patients and their families.

Some risk factors for the development of delirium well known, e.g. dementia, hypertension, illness severity (SAPS II score), delirium on the previous day, mechanical ventilation, emergency surgery and metabolic acidosis. The effect of sedative drug administration is not clear, as studies has been inconclusive.

Even though studies regarding the impact of sleep deprivation on development of delirium have been inconclusive, there is no doubt that delirious patients have a disturbed sleep-wake cycle, sleep architecture and circadian rhythm.

At the intensive care unit at the Department of Anesthesiology at Køge Hospital, three out of nine rooms have a simulated circadian light installed. The idea is that this light rhythm may help to keep a natural circadian rhythm, minimizing the risk of delirium.

With this descriptive and retrospective cohort study, the investigators therefore want to describe the incidence and possible risk- and preventive factors of delirium for the participants (ICU patients at Køge Hospital), and with a special focus on the possible effect of imitated circadian light..

Study Type

Observational

Enrollment (Actual)

183

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Køge, Denmark
        • Køge Sygehus

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Adult patients admitted to the ICU at Køge Hospital in the study period

Description

Inclusion Criteria:

  • Patients >18 years of age admitted to the ICU at Køge Hospital in the study period

Exclusion Criteria:

  • Richmond Agitation Sedation Score (RASS): -4 or -5 during the whole study period
  • No CAM-ICU scores during the ICU stay
  • Unable to communicate in Danish (aphasic, deaf, non-Danish speaking, severe brain damage)
  • Severe dementia documented in electronic patient charts (OPUS)
  • Patients not receiving active treatment (moribund patients)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Delirium at any time point
Time Frame: Throughout study period, up to 6 months
Incidence of patients with delirium during ICU-stay defined as at least one positive Confusion Assessment Method for the ICU (CAM-ICU) score or CAM-ICU negative delirium treated with anti-psychotics.
Throughout study period, up to 6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Days with delirium
Time Frame: Throughout study period, up to 6 months
Days with positive CAM-ICU or CAM-ICU negative delirium treated with anti-psychotics in relation to length of stay (LOS)
Throughout study period, up to 6 months
Circadian light exposure
Time Frame: Throughout study period, up to 6 months
Difference in incidences of delirium between patients admitted to rooms with circadian rhythm lighting and standard rooms
Throughout study period, up to 6 months
Delirium in patients treated with hypnotics
Time Frame: Throughout study period, up to 6 months
Difference in incidence of delirium in patients treated with hypnotics before admission to hospital (ATC N05C) compared to those who are not
Throughout study period, up to 6 months
Delirium in patients treated with steroids
Time Frame: Throughout study period, up to 6 months
Differences in incidences of delirium in patients that are treated with systemic steroids vs. no treatment
Throughout study period, up to 6 months
Mortality
Time Frame: Throughout study period, up to 6 months
Mortality within ICU stay
Throughout study period, up to 6 months
Demographic differences
Time Frame: Throughout study period, up to 6 months
Incidence of delirium associated to demographic variables (age, gender)
Throughout study period, up to 6 months
Delirium and Simplified Acute Physiology Score (SAPS)
Time Frame: Throughout study period, up to 6 months
Incidence of delirium associated to Simplified Acute Physiology Score (SAPS) II
Throughout study period, up to 6 months
Delirium related to number of ventilator days
Time Frame: Throughout study period, up to 6 months
Incidence of delirium associated to number of ventilator days
Throughout study period, up to 6 months
Delirium related to sedation
Time Frame: Throughout study period, up to 6 months
Incidence of delirium associated to sedation infusion
Throughout study period, up to 6 months
Delirium related to admission type
Time Frame: Throughout study period, up to 6 months
Incidence of delirium associated to admission type (medical/elective surgical/acute surgical)
Throughout study period, up to 6 months
Distribution of types of delirium
Time Frame: Throughout study period, up to 6 months
Incidence and distribution of delirium subtypes (hypoactive/hyperactive/mixed)
Throughout study period, up to 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Ole Mathiesen, MD, PhD, Køge Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2015

Primary Completion (Actual)

February 1, 2016

Study Completion (Actual)

February 1, 2016

Study Registration Dates

First Submitted

November 4, 2015

First Submitted That Met QC Criteria

November 10, 2015

First Posted (Estimate)

November 13, 2015

Study Record Updates

Last Update Posted (Actual)

July 2, 2018

Last Update Submitted That Met QC Criteria

June 29, 2018

Last Verified

June 1, 2018

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Delirium

Subscribe